Create an Account

ReachMD Briefs: Short Medical Videos

Welcome to ReachMD Briefs, your source for exclusive short video content on ReachMD. Each video provides medical insights in brief, easy-to-digest formats for when you only have a moment of time between patient visits. From the latest medical discoveries to obscure medical jargon, there’s something for everyone. So go ahead, explore our content and find something interesting to share with your patients or discuss around the wards. Who knows what you will discover?

Episodes 1-15 of 15

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00
    Adjuvant Nivolumab Alone or in Combination with Ipilimumab Versus Placebo in Stage IV Melanoma with No Evidence of Disease: Overall Survival Results of IMMUNED, a Randomized, Double-Blind Multi-Center Phase 2p DeCOG Trial
    Adjuvant Nivolumab Alone or in Combination with Ipilimumab Versus Placebo in Stage IV Melanoma with No Evidence of Disease: Overall Survival Results of IMMUNED, a Randomized, Double-Blind Multi-Center Phase 2p DeCOG Trial

    Learn More

    Adjuvant Nivolumab Alone or in Combination with Ipilimumab Versus Placebo in Stage IV Melanoma with No Evidence of Disease: Overall Survival Results of IMMUNED, a Randomized, Double-Blind Multi-Center Phase 2p DeCOG Trial
    UP NEXT...
    The HPV Data Is In — What Do the Newest Updates in Screening Mean For Your Patients?

    Welcome to the new
    Global Oncology Academy website.

    NEW FEATURES:

    • Check out all the new educational programs we have added.New educational programs
    • Now mobile-friendly and easier to navigate.Now mobile-friendly
    • A learner profile that stores your history/CME certificates.Track your credits
    Register

    We’re glad to see you’re enjoying Global Oncology Academy…
    but how about a more personalized experience?

    Register for free
    You are now leaving Global Oncology Academy and going to a site run by another organization.

    Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.